| Biological Sciences | Lifetime | 51 | IT 1 | 99.99 |
| Immunology | Lifetime | 3 | IT 1 | 100.00 |
| Oncology | Lifetime | 21 | IT 2 | 99.96 |
| Immunology and Allergy | Lifetime | 138 | IT 4 | 97.96 |
| Cancer Research | Lifetime | 914 | IT 23 | 93.00 |
| Immunology | 2021-2025 | 23 | IT 1 | 99.49 |
| Oncology | 2021-2025 | 581 | IT 33 | 91.46 |
| Infectious Diseases | 2021-2025 | 503 | IT 31 | 89.31 |
| Immune cells in cancer | Lifetime | 1 | IT 1 | 99.99 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 1 | IT 1 | 99.95 |
| Chemokine receptors and signaling | Lifetime | 1 | IT 1 | 99.99 |
| Immune Response and Inflammation | Lifetime | 5 | IT 1 | 99.97 |
| Biomarkers in Disease Mechanisms | Lifetime | 1 | IT 1 | 99.97 |
| Immune Cell Function and Interaction | Lifetime | 25 | IT 2 | 99.95 |
| Phagocytosis and Immune Regulation | Lifetime | 3 | IT 1 | 99.94 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 4 | IT 1 | 99.77 |
| Immunotherapy and Immune Responses | Lifetime | 30 | IT 1 | 99.94 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 40 | IT 2 | 99.89 |
| Cell Adhesion Molecules Research | Lifetime | 35 | IT 1 | 99.81 |
| Inflammasome and immune disorders | Lifetime | 14 | IT 1 | 99.82 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 27 | IT 1 | 99.74 |
| COVID-19 Clinical Research Studies | Lifetime | 140 | IT 13 | 99.21 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 39 | IT 3 | 99.43 |
| Reproductive System and Pregnancy | Lifetime | 103 | IT 6 | 99.15 |
| IL-33, ST2, and ILC Pathways | Lifetime | 51 | IT 2 | 99.29 |
| T-cell and B-cell Immunology | Lifetime | 261 | IT 6 | 99.46 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 344 | IT 12 | 98.75 |
| Cancer Research and Treatments | Lifetime | 207 | IT 3 | 98.59 |
| Cancer Cells and Metastasis | Lifetime | 266 | IT 11 | 98.74 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 196 | IT 10 | 98.44 |
| Circular RNAs in diseases | Lifetime | 294 | IT 14 | 98.01 |
| Immune responses and vaccinations | Lifetime | 70 | IT 3 | 97.27 |
| Angiogenesis and VEGF in Cancer | Lifetime | 355 | IT 20 | 97.79 |
| interferon and immune responses | Lifetime | 463 | IT 4 | 97.00 |
| Agricultural safety and regulations | Lifetime | 42 | IT 6 | 94.87 |
| Macrophage Migration Inhibitory Factor | Lifetime | 91 | IT 1 | 96.34 |
| NF-κB Signaling Pathways | Lifetime | 477 | IT 9 | 95.86 |
| Leptospirosis research and findings | Lifetime | 264 | IT 11 | 91.90 |
| Inflammation biomarkers and pathways | Lifetime | 506 | IT 15 | 79.22 |
| Immune cells in cancer | 2021-2025 | 10 | IT 1 | 99.51 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 1 | IT 1 | 99.33 |
| COVID-19 Clinical Research Studies | 2021-2025 | 198 | IT 16 | 98.97 |
| Immune Cell Function and Interaction | 2021-2025 | 120 | IT 4 | 98.19 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 416 | IT 18 | 98.27 |
| Immune Response and Inflammation | 2021-2025 | 61 | IT 1 | 95.11 |
| Phagocytosis and Immune Regulation | 2021-2025 | 39 | IT 1 | 93.29 |
| Long-Term Effects of COVID-19 | 2021-2025 | 612 | IT 86 | 94.88 |
| Chemokine receptors and signaling | 2021-2025 | 38 | IT 2 | 89.39 |
| Immunotherapy and Immune Responses | 2021-2025 | 694 | IT 13 | 92.67 |
| Cancer Cells and Metastasis | 2021-2025 | 621 | IT 29 | 87.24 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 918 | IT 42 | 73.08 |
| Immune responses and vaccinations | 2021-2025 | 490 | IT 9 | 68.67 |
| Agricultural safety and regulations | 2021-2025 | 841 | IT 195 | 16.71 |
